Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Graham who wrote (6749)	2/12/2001 7:43:24 PM
From: Joe Krupa	of 14101

Hi David, "? I don't know much about this company, but from what I can tell, they have a larger market cap and they haven't even filed for FDA approval yet. Nobody ever said the world was fair -- let alone the stock market. The valuation differences between Dimethaid and Hemosol have always been a peeve of mine -- $326 million for Dimethaid, and $594 million for HML. You are right, Hemosol has not even filed for FDA approval for Hemolink yet. Heck, they have not even completed their phase III trials for US and Europe yet. Furthermore, the market for blood substitutes is about $750 million, while around $6 billion for OA drugs. And quite frankly, Dimethaid has a much more exciting product pipeline than Hemosol. Aaaarrrrggggghhhh!!!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next